Lymphoma: Clinical Trials

Showing 1 - 50 of 64 trials
Titlesort icon Investigator
A Comprehensive Assessment to Predict Side Effects from Chemotherapy and an Evaluation of Pre-Phase Chemotherapy in Older Patients with Non-Hodgkin Lymphoma
[Protocol 13-028]
Hamlin, Paul, MD
A Long-Term Study of Sexual and Reproductive Health in Women with Breast Cancer and Lymphoma
[Protocol 12-249]
Goldfarb, Shari, MD
A Phase I Study of ABT-199 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 11-152]
Gerecitano, John, MD, PhD
A Phase I Study of BMS-906024 in Adult and Pediatric Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma
Relapsed/Refractory
[Protocol 11-181]
Douer, Dan, MD
A Phase I Study of CB-839 in Patients with Advanced or Persistent Hematologic Cancers
[Protocol 14-053]
Younes, Anas, MD
A Phase I Study of CPI-0610 in Patients with Progressive Lymphoma
Relapsed/Refractory
[Protocol 13-259]
Younes, Anas, MD
A Phase I Study of CUDC-907 in Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Relapsed/Refractory
[Protocol 13-045]
Younes, Anas, MD
A Phase I Study of DS-3032B in Patients with Advanced Solid Tumors or Lymphomas
[Protocol 13-171]
Gounder, Mrinal, MD
A Phase I Study of High-Dose Therapy and Autologous Stem Cell Transplantation Followed by Modified T Cells for Aggressive B-Cell Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 12-117]
Sauter, Craig, MD
A Phase I Study of Ibrutinib plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (R-ICE) in Patients with Recurrent or Persistent Diffuse Large B-Cell Lymphoma
[Protocol 14-145]
Sauter, Craig, MD
A Phase I Study of IMGN529 in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma
[Protocol 13-073]
Palomba, M. Lia, MD
A Phase I Study of LDK378 in Children with Cancers Containing an ALK Mutation
Relapsed/Refractory
[Protocol 13-235]
Modak, Shakeel, MD
A Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Hematologic Cancers
Relapsed/Refractory
[Protocol 12-142]
Lesokhin, Alexander, MD
A Phase I Study of PF-05082566 Alone in Patients with Advanced Cancer, and in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
[Protocol 11-085]
Segal, Neil, MD, PhD
A Phase I Study of Pomalidomide in Patients with Recurrent or Persistent Primary Central Nervous System Lymphoma or Primary Vitreoretinal Lymphoma
Relapsed/Refractory
[Protocol 14-003]
Grommes, Christian, MD
A Phase I Study of PRT062070 in Patients with Persistent or Recurrent Chronic Lymphocytic Leukemia, Small Cell Lymphocytic Leukemia, or B-Cell Non-Hodgkin Lymphoma
[Protocol 14-023]
Hamlin, Paul, MD
A Phase I Study of PU-H71 in Patients with Advanced Cancer
[Protocol 11-041]
Gerecitano, John, MD, PhD
A Phase I Study of SGN-CD19A in Children and Adults with Persistent B-Cell Acute Lymphoblastic Leukemia or Aggressive Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 13-106]
Trippett, Tanya, MD
A Phase I Study of SGN-CD19A in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 12-282]
Moskowitz, Craig, MD
A Phase I Study of VS-5584 in Patients with Lymphoma or Advanced Solid Tumors
[Protocol 14-065]
Varghese, Anna, MD
A Phase I/II Study Assessing BPX-501 T Cells Given After Partially Mismatched Related T Cell-Depleted Stem Cell Transplantation in Patients with Hematologic Cancers
[Protocol 13-181]
Perales, Miguel-Angel, MD
A Phase I/II Study of Brentuximab (SGN-35) in Pediatric Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma or Hodgkin Lymphoma
Relapsed/Refractory
[Protocol 11-210]
Trippett, Tanya, MD
A Phase I/II Study of GSK525762 in Patients with Persistent Hematologic Cancers
[Protocol 13-202]
Stein, Eytan, MD
A Phase I/II Study of Ibrutinib in Patients with Recurrent or Persistent Central Nervous System (CNS) Lymphoma
Relapsed/Refractory
[Protocol 14-184]
Grommes, Christian, MD
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders
[Protocol 95-024]
O'Reilly, Richard, MD
A Phase I/II Trial of Vorinostat and Risk-Adapted Chemotherapy with Rituximab in HIV-Related B-Cell Non-Hodgkin's Lymphoma
Newly Diagnosed
[Protocol 11-013]
Noy, Ariela, MD
A Phase IB Study of GDC-0199 (ABT-199 or Venetoclax) with R-CHOP or G-CHOP in Patients with B-Cell Non-Hodgkin Lymphoma
[Protocol 14-130]
Zelenetz, Andrew, MD, PhD
A Phase IB Study of MK-3475 in Patients with Myelodysplastic Syndromes and Lymphoma
Relapsed/Refractory
[Protocol 13-220]
Moskowitz, Craig, MD
A Phase Ib Study of Urelumab Given with Rituximab in Patients with Recurrent or Persistent Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Relapsed/Refractory
[Protocol 13-252]
Zelenetz, Andrew, MD, PhD
A Phase Ib/II Study of AEB071 and Everolimus in Patients with CD79-Mutant or ABC Diffuse Large B-Cell Lymphoma
[Protocol 13-225]
Gerecitano, John, MD, PhD
A Phase IB/IIA Study of Romidepsin plus Lenalidomide in Adults with Relapsed or Refractory Lymphoma and Myeloma
Relapsed/Refractory
[Protocol 12-170]
Horwitz, Steven, MD
A Phase II Study Comparing Three New Approaches for Preventing Graft-versus-Host Disease
[Protocol 14-197]
Giralt, Sergio, MD
A Phase II Study Evaluating the Use of Donated EBV-Immune T Cells to Treat Transplant Recipients with EBV
[Protocol 11-130]
O'Reilly, Richard, MD
A Phase II Study of Brentuximab (SGN-35) Given Before and After Adriamycin, Vinblastine, and Dacarbazine Therapy in Older Adults with Untreated Hodgkin Lymphoma
[Protocol 11-201]
Hamlin, Paul, MD
A Phase II Study of Bulk Versus Fractionated Stem Cell Infusions in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 12-016]
Giralt, Sergio, MD
A Phase II Study of Buparlisib in Patients with Recurrent or Persistent Central Nervous System (CNS) Lymphoma
Relapsed/Refractory
[Protocol 14-177]
Grommes, Christian, MD
A Phase II Study of Combination Chemotherapy with and without Low-Dose Whole-Brain Radiation for Primary Central Nervous System Lymphoma
[Protocol 11-125]
Omuro, Antonio, MD
A Phase II Study of Dose-Adjusted EPOCH Chemotherapy with or without Rituximab in Patients with Untreated Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, or Plasmablastic Lymphoma
[Protocol 13-022]
Noy, Ariela, MD
A Phase II Study of Ibrutinib in Patients with Persistent or Recurrent Marginal Zone Lymphoma
[Protocol 14-058]
Noy, Ariela, MD
A Phase II Study of KW-0761 or Standard Therapy in Patients with Previously Treated Adult T-Cell Leukemia-Lymphoma
[Protocol 12-251]
Horwitz, Steven, MD
A Phase II Study of Mocetinostat in Patients with Diffuse Large B-cell Lymphoma or Follicular Lymphoma with Certain Mutations
[Protocol 14-106]
Younes, Anas, MD
A Phase II Study of Moxetumomab Pasudotox in Children with Acute Lymphocytic Leukemia or Lymphoblastic B-Cell Lymphoma: the MOXIE Study
Relapsed/Refractory
[Protocol 13-206]
Trippett, Tanya, MD
A Phase II Study of Nivolumab in Patients with Classical Hodgkin Lymphoma that Has Returned After Autologous Stem Cell Transplantation
[Protocol 14-147]
Younes, Anas, MD
A Phase II Study of Palifermin with or without Leuprolide After T-Cell-Depleted Allogeneic Stem Cell Transplantation
[Protocol 12-077]
Goldberg, Jenna, MD
A Phase II Study of Romidepsin after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma
[Protocol 13-020]
Horwitz, Steven, MD
A Phase II Trial of Transplants from HLA-Compatible Donors with T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System for the Treatment of Patients with Hematologic Malignancies and Disorders
[Protocol 10-050]
O'Reilly, Richard, MD
A Phase III Randomized Study of Expanded Umbilical Cord Blood Cells to Enhance Blood System Recovery in Patients with Hematologic Cancers Undergoing Stem Cell Transplantation
[Protocol 13-214]
Barker, Juliet, MBBS
A Phase III Study of Bendamustine and Rituximab with or without Ibrutinib in Older Patients with Newly Diagnosed Mantle Cell Lymphoma
[Protocol 13-196]
Hamlin, Paul, MD
A Phase III Study of Brentuximab Vedotin plus CHP versus CHOP Therapy for Patients with Previously Untreated CD30-Positive Peripheral T-Cell Lymphoma
[Protocol 13-055]
Horwitz, Steven, MD
A Phase III Study of Brentuximab Vedotin versus Standard Therapy in Patients with Cutaneous T-Cell Lymphoma
[Protocol 13-008]
Horwitz, Steven, MD